Literature summary for 3.4.14.5 extracted from

Rosenstock, J.; Brazg, R.; Andryuk, P.J.; Lu, K.; Stein, P.; Stein, P.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (2006), Clin. Ther., 28, 1556-1568.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	in a 24-week study, sitagliptin 100 mg once daily added to ongoing pioglitazone therapy is effective and well tolerated in these patients with type 2 diabetes who had not achieved adequate glycemic control with pioglitazone alone	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
sitagliptin	in a 24-week study, sitagliptin 100 mg once daily added to ongoing pioglitazone therapy is effective and well tolerated in these patients with type 2 diabetes who had not achieved adequate glycemic control with pioglitazone alone	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with type 2 diabetes	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)